郭桂喜 1李娟娟 1刘传梅 1徐建祥 1闫晓芸 1李慧 1张磊 2董砚虎2
作者信息
- 1. 潍坊医学院临床医学系，山东潍坊261042
- 2. 青岛市内分泌糖尿病医院，山东青岛266071
- 折叠
摘要
Abstract
Objective To Investigate the effect of the GLP-1 receptor agonist on patients with type 2 diabetes mellitus (T2DM) between the short-term and long-term metabolic control. Methods 120 patients with T2DM treated with Exenatide in Qingdao Endocrinology Diabetes Hospital from 2010 to 2013 were divided into two groups due to the term of drug use. Patients in group A (n=58) applied Exenatide not less than 24 weeks,while those in goup B (n=62) more than 24 weeks. Indicates included body weight (before and after the treatment), WC, HC, FBG, P2Hbg, HbA1C, TG, TC, LDL, HDL, SBP, DBP, BMI, WSR, WHR, BMD, and body fat content. Results The body weight, BMI and the body fat content in two groups were both decreased than that before treatment, which had no significant difference in the comparison between groups (P>0.05); WC, WSR, FBG, P2hBG, HbA1C, SBP, DBP in two groups were both decreased than that before treatment, which had statistically significant difference in the comparison between the two groups (P < 0.05).TG, TC, LDL, HDL in two groups had no statistically different neither before nor after treatment (P > 0.05). Neither the gastrointestinal adverse reaction nor the rate of hypoglycemia in the two groups had no statistically different in the comparison between groups (P>0.05). Conclusion The better clinical effect of GLP-1 receptor agonists for T2DM lies in long-term application, which can also decrease the risk of the gastrointestinal reactions and hypoglycemia, redistribute the body fat and improve abdominal obesity and insulin resistance.关键词
2型糖尿病/艾塞那肽/体脂分布Key words
Type 2 diabetes mellitus/Exenatide/Body fat distribution分类
医药卫生
